Skip to content

Efficacy and safety of Simiao pill in the treatment of hyperuricemia

Efficacy and safety of Simiao pill in the treatment of hyperuricemia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005345
Enrollment
Unknown
Registered
2021-11-28
Start date
2021-11-17
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Sponsors

Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. In accordance with the diagnostic criteria of hyperuricemia, or conform to the diagnostic criteria of people of good health status; 2. Aged 18 to 30 years male and female; 3. The subjects of hyperuricemia conforms to the clinical syndrome diagnosis standard of damp heat syndrome in traditional Chinese medicine; 4. The subjects are informed and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Living with a serious adverse lifestyle; 2. With any infection in recent four weeks; 3. Pregnant or lactating women, or people who are allergic to the test drug; 4. Subjects who are taking part in other drugs clinical trials; 5. Volunteers whom researchers believe not suitable for the clinical trail with other reasons; 6. Hereditary disease; 7. Use of antibiotics, probiotics, prebiotics, or synbiotics in two months before collection of the fecal sample.

Design outcomes

Primary

MeasureTime frame
uric acid production and excretion; the score of damp heat syndrome;uric acid;

Secondary

MeasureTime frame
blood lipid;blood glucose;liver function;renal function;

Countries

China

Contacts

Public ContactZhao Xiaoshan

Southern Medical University

zhaoxs0609@163.com+86 18620277055

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026